Compare BIO-TECHNE Corp (TECH) vs United States Oil ETF (USO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs United States Oil ETF — how do they compare? BIO-TECHNE Corp trades at $72.46 (market cap $11.37B), while United States Oil ETF trades at $146.65 (market cap $1.83B). The key difference: BIO-TECHNE Corp is far larger — about 6.2× United States Oil ETF's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while United States Oil ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 63 Days and United States Oil ETF for 21 Days on average.
| TECH | USO | |
|---|---|---|
Market Cap | $11.37B | $1.83B |
Volume | 3,153,511 | 3,073,172 |
Sector | Health | — |
52-Week High | $72.61 | $161.86 |
52-Week Low | $43.31 | $66.17 |
Typical Hold Time | 63 Days | 21 Days |
Enterprise Value | $11.40B | — |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
USO trades at $143.91, down 0.7% amid mixed oil market signals. Technical indicators show neutral momentum with bearish moving averages, while geopolitical tensions and supply dynamics dominate sentiment. The stock faces resistance at $145 and support at $142, with recent news highlighting Middle East conflicts and OPEC+ production decisions affecting energy sector volatility.
The outlook remains uncertain with competing pressures from geopolitical risks and coordinated reserve releases. Investment opportunities exist if supply disruptions persist, but risks include potential price stabilization from G-7 interventions and broader market volatility. Current technical positioning suggests cautious near-term trading with key levels defining directional bias.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About United States Oil ETF
This ETF invests primarily in futures contracts for light, sweet crude oil, other types of crude oil, diesel-heating oil, gasoline, natural gas, and other petroleum-based fuels.
Read more on USO →
